In draft guid­ance, NICE fails to back Clo­vis's PARP in­hibitor Rubra­ca

De­spite the EMA’s en­dorse­ment of Clo­vis’s can­cer treat­ment Rubra­ca last year, the UK’s cost-ef­fec­tive­ness watch­dog NICE has rec­om­mend­ed against the adop­tion of the drug in the Na­tion­al Health Ser­vice (NHS).

Rubra­ca is ap­proved for use in the EU as monother­a­py for the main­te­nance treat­ment of adult pa­tients with high-grade ep­ithe­lial ovar­i­an, fal­lop­i­an tube, or pri­ma­ry peri­toneal can­cer who have re­lapsed af­ter  plat­inum-based chemother­a­py. The drug was orig­i­nal­ly de­vel­oped at New­cas­tle Uni­ver­si­ty, with a team in­volv­ing re­searchers from the North­ern In­sti­tute for Can­cer Re­search and Can­cer Re­search UK-fund­ed sci­en­tists. It gen­er­at­ed sec­ond-quar­ter sales of $33 mil­lion glob­al­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER